Mandate

Vinge advises Fastighets AB Trianon in connection with its listing on Nasdaq Stockholm

Vinge has advised Fastighets AB Trianon (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm’s main market.

The prospectus was published on 15 December 2020 and the trading on Nasdaq Stockholm commenced on 17 December 2020.

Vinge’s team primarily consisted of Christian Lindhé, Erik Sjöman, Astrid Isberg and Sophia Reutercrona (Capital markets and public M&A) as well as Anna Edström and Philip Åberg (M&A).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026